Good GTXI stuff: "So where we are now, we're finishing up our -- we're in a middle of our Phase II in metastatic castrate resistant prostate cancer our goal by the second half of the year is to be able to provide some information in the open label study.
Where we stand financially, we have 62.8 million shares outstanding. Cash, cash equivalents of 42.2 million as of March 31st. There is no debt and we have no warrants. So in summary we have lot going on GTx, a has finished its two Phase III programs in a new indication for prevention and treatment of muscle wasting."
News 
Market Data 
Discover 
AI
